4-(1-Thiazol-2-yl-ethylaMino)-piperidine-1-carboxylic acid tert-butyl ester
![]() |
- $428 - $1175.9
- Product name: 4-(1-Thiazol-2-yl-ethylaMino)-piperidine-1-carboxylic acid tert-butyl ester
- CAS: 1289387-85-4
- MF: C15H25N3O2S
- MW: 311.44
- EINECS:
- MDL Number:MFCD18837545
- Synonyms:4-(1-Thiazol-2-yl-ethylaMino)-piperidine-1-carboxylic acid tert-butyl ester;tert-Butyl 4-((1-(thiazol-2-yl)ethyl)aMino)piperidine-1-carboxylate;1-Piperidinecarboxylic acid, 4-[[1-(2-thiazolyl)ethyl]amino]-, 1,1-dimethylethyl ester
3 prices
Selected condition:
Brand
- Alichem
- Crysdot
Package
- 250mg
- 1g
- ManufacturerAlichem
- Product number1289387854
- Product descriptiontert-Butyl4-((1-(thiazol-2-yl)ethyl)amino)piperidine-1-carboxylate
- Packaging1g
- Price$1175.9
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11299483
- Product descriptiontert-Butyl4-((1-(thiazol-2-yl)ethyl)amino)piperidine-1-carboxylate 95+%
- Packaging250mg
- Price$428
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11299483
- Product descriptiontert-Butyl4-((1-(thiazol-2-yl)ethyl)amino)piperidine-1-carboxylate 95+%
- Packaging1g
- Price$1069
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Alichem | 1289387854 | tert-Butyl4-((1-(thiazol-2-yl)ethyl)amino)piperidine-1-carboxylate | 1g | $1175.9 | 2021-12-16 | Buy |
Crysdot | CD11299483 | tert-Butyl4-((1-(thiazol-2-yl)ethyl)amino)piperidine-1-carboxylate 95+% | 250mg | $428 | 2021-12-16 | Buy |
Crysdot | CD11299483 | tert-Butyl4-((1-(thiazol-2-yl)ethyl)amino)piperidine-1-carboxylate 95+% | 1g | $1069 | 2021-12-16 | Buy |
Properties
Boiling point :407.0±40.0 °C(Predicted)
Density :1.15±0.1 g/cm3(Predicted)
storage temp. :2-8°C
pka :6.90±0.20(Predicted)
Density :1.15±0.1 g/cm3(Predicted)
storage temp. :2-8°C
pka :6.90±0.20(Predicted)
Safety Information
Symbol(GHS): | ||||||||
---|---|---|---|---|---|---|---|---|
Signal word: | ||||||||
Hazard statements: |
|
|||||||
Precautionary statements: |
|